Gide, counsel to Inserm Transfert Initiative and Versant Ventures on their investment in AAVLife

Gide has advised Inserm Transfert Initiative and Versant Ventures on their 12-million-dollar investment in the share capital of AAVLife, a company specialising in gene therapy for rare diseases, in particular the heart dysfunction associated with Friedreich’s Ataxia.  

Legal counsel to Inserm Transfert Initiative and Versant Ventures:
Gide, Karen Noël (partner) and Pierre-Emmanuel Sirgue.

Legal counsel to AAVLife:
King & Wood Mallesons SJ Berwin, Pierre-Louis Périn (partner) and Rémi Pagès.